Phase 2 N=40 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=229 Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Pancreatic Adenocarcinoma
Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants
Phase 2 N=50 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Phase 1 N=35 BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
Metastatic Pancreatic Cancer
Primary: Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer. — 1; 1; 2 participants
Phase 2 N=34 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Phase 2 N=28 FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Locally Advanced Pancreatic Cancer · Pancreatic Cancer
Primary: Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. — 0; 12; 12; 4 Participants
Phase 1 N=27 A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
Metastatic Pancreatic Cancer
Primary: Toxicity (Number of Patients Who Experiened DLTs) — 0; 1; 1; 2 participants
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=33 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
Pancreatic Cancer
Primary: Number of Participants With Resectability Rate — 15 Participants
Phase 2 N=25 BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Pancreatic Cancer
Primary: Feasibility of Adjuvant FOLFOX-A — 18 Participants
Phase 2 N=39 Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants
Phase 2 N=39 Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Pancreatic Cancer
Primary: Overall Survival at 18 Months — 63 percentage of participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=83 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Overall Survival (OS) — 9.38; 14.7 Months
Phase 2 N=112 Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Phase 2 N=20 Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Patients Alive — 10 participants
Phase 2 N=8 AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Pancreatic Neoplasms
Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026
Phase 2 N=25 INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Phase 2 N=27 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
Pancreatic Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) — 0; 0 Percent of Participants
Phase 1 N=18 Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD) — 0; 2; 2 participants
Phase 3 N=154 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
Phase 2 N=58 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Phase 2 N=273 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
Metastatic Pancreatic Cancer
Primary: Percentage of Patients Alive and Without Radiological and/or Clinical Progression 6 Months After the Randomization. — 41; 39; 30 Participants
Phase 2 N=50 Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Progression-free Survival — 5.7 months
Phase 2 N=37 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Phase 3 N=861 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001
Phase 2 N=10 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Colon Cancer · Pancreatic Cancer · Cholangiocarcinoma
Primary: Number of Participants With Disease Recurrence At 1 Year — 2; 0 Participants
Phase 2 N=51 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Adenocarcinoma · Colorectal Cancer · Ovarian Cancer
Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…
Phase 2 N=11 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants